Our onco-metabolism approach brings
an enhanced perspective to cancer.
- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Therapeutic Areas
- Oncology
- Cystic Fibrosis
- Publications
- Programs
- Pipeline
- Glutaminase Inhibitor Telaglenastat
- Arginase Inhibitor Oncology
- Arginase Inhibitor
Cystic Fibrosis - CD73 Inhibitor
CB-708 - IL4I1 Inhibitor
- Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Media & Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
-
Calithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent Highlights
-
UPDATE – Calithera Biosciences to Report Fourth Quarter 2020 Financial Results on Tuesday, March 16, 2021
-
Calithera Biosciences to Report Fourth Quarter 2021 Financial Results on Tuesday, March 16, 2021
-
Calithera to Present at the H.C. Wainwright Virtual Global Life Sciences 2021 Conference
-
Calithera to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
Targeting cancer, differently.
Targeting cancer, differently.
Our onco-metabolism approach brings
an enhanced perspective to cancer.Targeting cancer, differently.
Our onco-metabolism approach brings
an enhanced perspective to cancer.Development Pipeline
Calithera is pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.
Development Pipeline
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.
Recent News